(Q35004084)

5 August 2017

Influenza recombinant vaccine: matrix protein M1 on the platform of the adenovirus dodecahedron (English)

1 reference

5 August 2017

1 reference

2

E Szolajska

1 reference

5 August 2017

A Naskalska

1

0 references

author name string

L Chaperot

3

1 reference

5 August 2017

J Angel

4

1 reference

5 August 2017

J Plumas

5

1 reference

5 August 2017

J Chroboczek

6

1 reference

5 August 2017

language of work or name

English

0 references

publication date

18 September 2009

1 reference

5 August 2017

1 reference

5 August 2017

27

1 reference

5 August 2017

52

1 reference

5 August 2017

7385-7393

1 reference

From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza.

5 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.021

Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.021

Virus-like particles as immunogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.021

Virus-like particles: passport to immune recognition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.021

Vaccine manufacturing: challenges and solutions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.021

Vaccination, immune and gene therapy based on virus-like particles against viral infections and cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.021

More than one reason to rethink the use of peptides in vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.021

Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.021

Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.021

The immunodominant influenza matrix T cell epitope recognized in human induces influenza protection in HLA-A2/K(b) transgenic mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.021

Functional constraints of influenza A virus epitopes limit escape from cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.021

Expression and purification of an influenza hemagglutinin--one step closer to a recombinant protein-based influenza vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.021

Human memory CTL response specific for influenza A virus is broad and multispecific

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.021

Influenza A virus matrix protein 1-specific human CD8+ T-cell response induced in trivalent inactivated vaccine recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.021

Adenovirus 3 penton dodecahedron exhibits structural changes of the base on fibre binding.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.021

Adenovirus dodecahedron, a new vector for human gene transfer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.021

Protein transduction into human cells by adenovirus dodecahedron using WW domains as universal adaptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.021

Synthesis, cellular localization, and quantification of penton-dodecahedron in serotype 3 adenovirus-infected cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.021

Adenovirus dodecahedron allows large multimeric protein transduction in human cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.021

Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.021

A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.021

Influenza virus M1 protein binds to RNA through its nuclear localization signal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.021

Adenovirus dodecahedron, as a drug delivery vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.021

Virosome-mediated delivery of tumor antigen to plasmacytoid dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.021

Whole lymphoma B cells allow efficient cross-presentation of antigens by dendritic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.021

Adenovirus protein involved in virus internalization recruits ubiquitin-protein ligases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.021

Immunobiology of dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.021

Antigenic differences between H5N1 human influenza viruses isolated in 1997 and 2003.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.021

Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.021

Cell-mediated protection in influenza infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.021

Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.021

Influenza A specific cytotoxic T-cell clones that do not recognize viral glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.021

Recognition of influenza A virus nucleoprotein by human cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.021

Identification of viral molecules recognized by influenza-specific human cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.021

Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.021

Cytotoxic T-cell immunity to influenza.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.021

Recent advances and novel strategies in vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.021

Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.021

Nanoparticles target distinct dendritic cell populations according to their size

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.021

Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.021

Evolutionary analysis of the influenza A virus M gene with comparison of the M1 and M2 proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.021

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2009.09.021

1 reference

5 August 2017

1 reference